A Japanese biotech firm has developed a new form of stem cell aimed at reducing the body’s immune rejection response.
Healios has created ‘universal donor cells’ (UDCs) using gene-editing technology that allows them to reduce the body’s immune rejection response.
The development will allow for the creation of regenerative pharmaceutical products with a lower risk of immune rejection, while preserving the inherent ability of the cells to replicate themselves continuously.
UDCs are induced pluripotent stem cells created using gene-editing technology that allows them to reduce the body’s immune rejection response.
Their production involves the removal of certain genes that elicit a rejection response, the introduction of an immunosuppression gene to improve immune evasion, and the addition of a suicide gene serving as a safety mechanism.
Healios plans to combine its UDC technology with its existing efforts in next-generation cancer-targeting immune cells to create a line of regenerative medicine therapies with the highest possible safety and efficacy profile.
Typically, transplanted cells trigger an immune rejection response in patients whose human leukocyte antigen (HLA) type does not match that of the cells.
HLA is an important molecule expressed in all human cells that is involved in how the immune system functions.
Any substance in an individual’s body with an HLA type that differs from the individual’s own is recognised as a foreign substance, which triggers an immune response that rejects and attacks that substance. Therefore, ensuring a match of HLA types is extremely important in organ transplantation.
Therefore, doctors must administer an immunosuppressant drug during transplantation, which increases the burden on the patient’s body.
To avoid the administration of immunosuppressants, it is preferable to utilise autologous iPS cells produced by the patient’s own cells, but the production process both takes a long time and is very expensive.
Healios pioneers regenerative medicines in Japan, using gene-modified stem cells (iPSCs) to develop regenerative treatments in immune-oncology cell therapies targeting solid tumors and liver diseases, and ophthalmology.
It was established in 2011 and to date has raised over US$330 million in funds to support its growth and development.
The Company has been listed on the Tokyo Stock Exchange since 2015.
TheHill secures UK gov funding and Barclays support to help advance digital innovation
Real time data collection changes the game for the stroke patient pathway
Inside BT’s mission to boost NHS connectivity
UCB and Open Medical partnership will support Fracture Liaison Services
Radar Healthcare announces Aamal Medical partnership
Photodisinfectant: can light curb the antimicrobial resistance crisis?
Video games may help teens discuss mental health
Why it’s time to revisit workplace mental health initiatives and make them work for everyone
Innovations in self-diagnostics technology: Paving the way to a healthier future?
Telehealth solution revolutionising stroke care in Cardiff and Vale UHB
- News4 weeks ago
TheHill launches NHS Market Access Accelerator recruitment for 2024 programme
- News2 weeks ago
Why a leading healthcare CEO sees recombinant DNA as a metaphor for developing breakthrough technologies
- Medtech3 weeks ago
Surtex Instruments to unveil game-changing Infinex microsurgery instruments at MEDICA
- AI1 week ago
Humans make better cancer treatment decisions than AI, study finds